Elevance Health EVP & Chief Digital Info Ofr Sold Shares Worth Over $572K

Elevance Health's EVP & Chief Digital Info Ofr, Lavu Ratnakar, sold 1,300 shares at $440 each, totaling $572,000. Ratnakar now directly owns 14,849 shares, according to an SEC filing.

Original reporting
Published Nov 6, 2026, 9:40 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 9:50 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Elevance Health EVP & Chief Digital Info Ofr Sold Shares Worth Over $572K — source image
Decision brief

The 30-second read

$ELVNeutralLow
01

Why it matters

The sale is modest and unlikely to move the stock significantly, but it adds to the flow of insider activity data.

02

Market read

A routine insider sale with limited trading relevance.

03

What to watch

Potential upcoming compensation changes or internal restructuring not disclosed.

Relevance 4/10Novelty 4/10Timing: today

Background

Form 4 filing disclosed by the SEC showing an insider transaction.

Company-level read

Ticker impact

$ELVNeutralHigh confidence
Context

EVP & Chief Digital Info Officer Lavu Ratnakar sold 1,300 shares for $572,000, reducing his stake to 14,849 shares.

Expected impact

likely slight pressure as the market prices in the insider sale

Evidence & confidence

The transaction size is modest but represents a direct sale by a senior executive, which can be interpreted as a weak negative signal.

Market effects

Minimal impact on the health insurance sector.

U.S. market only; no broader regional effect.

Low; the filing is a routine insider transaction.

Counterpoint

The sale could be unrelated to company fundamentals and merely personal liquidity needs.

Key entities

  • Elevance Health

    U.S.-listed health insurance provider (ticker ELV).

  • Lavu Ratnakar

    EVP & Chief Digital Information Officer at Elevance Health.

Related articles

$ELVMed

The Perfect Child Sued by Elevance Health over $800M in Fraudulent Billing

Elevance Health (NYSE: ELV) sued The Perfect Child ABA and its founder, alleging $800M in fraudulent billing since 2021. The suit claims deceptive practices, inflated prices, and threats to patients' families. Elevance Health paid $160M to The Perfect Child ABA. The company is also facing a federal lawsuit by a parent for $363,816.17 in alleged surprise billing.

$CNCMed

Health insurers, hospitals rally after sweeping midterm win for Democrats

Shares of Medicaid-focused health insurers (Centene, Elevance, Molina) and hospital operators (HCA, Tenet, Universal) rose after Democrats won the midterms, raising hopes for sector-friendly policies. Analysts expect delays in Trump's OBBBA, easing pressure on Medicaid and ACA insurers, and potential extensions of enhanced subsidies. Year-to-date gains vary among companies.

$CVSMed

Aetna, Elevance, and Four Other Insurers Say the Medicare Advantage Star Rating System Is Broken — Now They Are Suing

CVS Health's Aetna subsidiary, along with Elevance Health, SCAN Health Plan, Alignment Healthcare, Healthfirst, and Centene, sued CMS over Medicare Advantage star ratings. They allege CMS used invalid measures, leading to lower ratings and $2B+ in lost bonus payments for Aetna. CMS has not responded. Ratings affect benefits for 4.2M Aetna members and $12.7B in annual bonuses.

Med

Elevance Earns $1.4 Billion Quarterly Profit as Membership Falls by 487,000 and Insurer Calls 2026 the Medicaid Trough

Elevance Health reported a $1.4B Q3 profit, up from $1.2B a year earlier, with 44.9M members, down 487K. The company expects 2026 to be the low point for Medicaid margins, with improvement in 2027. Elevance raised its full-year outlook to at least $29 per share, but is exiting some Medicaid markets and tightening spending. Medicaid work requirements begin in January 2027, potentially affecting 2.3M people.

$ELVMed

BofA raises Elevance stock price target to $500 on earnings beat

BofA Securities raised its price target for Elevance Health (ELV) to $500 from $480, citing a 10% Q3 earnings beat and raised 2026 guidance. The company's market cap is $94.2B, P/E ratio 19.62. BofA highlights seven 2027 tailwinds, including margin improvements and share buybacks. ELV reported Q3 EPS of $6.99 vs. $4.70 estimate, revenue of $50.4B vs. $49.32B estimate.